Memorial Sloan Kettering researchers uncover how pancreatic cancer cells suppress immune triggers by manipulating genetic elements.
Memorial Sloan Kettering researchers uncover how pancreatic cancer cells suppress immune triggers by manipulating genetic elements.
A new research center and FDA-backed diversity mandates aim to reshape clinical trial equity and representation across the …
AbbVie’s Emraclidine Misses Mark in Schizophrenia Trials—But Safety Signals Keep Hope Alive
Novo Nordisk’s oral obesity drug shows superior efficacy over Eli Lilly’s candidate, reshaping the competitive landscape in metabolic …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
In a surprising move, Novartis snapped up preclinical-stage Kate Therapeutics for over a billion dollars—signaling renewed confidence in …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
Cutting-edge biomarker technologies are enabling faster, more accurate cancer diagnosis and tailored therapies, revolutionizing precision oncology.
Already a subscriber? Log in